https://charts.traderzeitung.de/phases/CA29842P1053
string(1422) "{"isin":"CA29842P1053","name":"Eupraxia Pharmaceuticals Inc","stock_id_xnas":43043392,"stock_id_xnys":null,"generated_at":"2026-08-21 19:58:00","days":[{"date":"2026-08-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":6.99,"close_at":"2026-08-19 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":6.73,"close_at":"2026-08-20 21:59:00","complete":true,"perf_pct":-3.7196},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":6.6,"close_at":"2026-08-21 15:14:00","complete":true,"perf_pct":-1.9316},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":6.7,"close_at":"2026-08-21 19:46:00","complete":false,"perf_pct":1.5152},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Eupraxia Pharmaceuticals Aktie News & Nachrichten
Trading-Room

Eupraxia Pharmaceuticals Aktie News & Nachrichten

[WKN: A3EGRS | Symbol: EPRX]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel
Trader-Zeitung Agents
Agentische Berichterstattung zu Eupraxia Pharmaceuticals
Kursziele und Analysen
Analystenmeinungen zu Eupraxia Pharmaceuticals

Artikel aus der Redaktion der Trader-Zeitung

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals: Wie gezielte Wirkstofffreisetzung Milliardenmärkte adressiert – Oppenheimer sieht massives Kurspotenzial

Von der systemischen zur lokalen Therapie: Das Geschäftsmodell Eupraxia Pharmaceuticals Inc. (EPRX)...

Eupraxia Pharmaceuticals Inc. (EPRX): Cantor Fitzgerald sieht 108 % Kurspotenzial!

Momentan fällt eine Eupraxia Pharmaceuticals Inc. (EPRX) positiv auf. Der Biotech hat sich auf die...

TOP-5-Kursziele der Analysten am 24.07.25

AxoGen Inc. [US05463X1063] Lake Street bestätigt Buy-Rating mit Kursziel 30 USD (123 % Kurspotenzial)...

  • ‹
  • 1
  • ›
Eupraxia Pharmaceuticals Nachrichtenticker öffnen
MT Newswires 28.07.2026 13:30 Uhr

Größte Verlierer im vorbörslichen Handel

07:29 AM EDT, 28.07.2026 (MT Newswires) -- Die Aktien von FiEE (FIEE) gaben im vorbörslichen Handel am Dienstag um 20 % nach, nachdem sie in der vorhe